Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

MCI: early-phase trial registry

4 of 6 indexed MCI trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

MCI: 6 US clinical trials tracked, 4 recruiting.

MCI is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 3 of these trials.

Enrollment posture brief

Registry condition mci

OPEN 4 | RECR 67% | LATE 0 | EARLY 1 | RANK #2866 | SPON 3

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

MCI (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near MCI

MCI lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MCI on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MCI is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates MCI research.

    University of California, San Francisco accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical MCI enrolment sits around 106 participants.

    Median target enrolment is 106 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.

  4. MCI research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on MCI records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MediTrain Device
3 trials
Worder Device
2 trials
wrist worn multi-sensor watches Device
2 trials
the radiotracer 18F-AV-1451 Drug
1 trials
noninvasive neurostimulation device Device
1 trials
[11C]PIB Drug
1 trials
[18F]MK6240 Drug
1 trials
[ 18f]3f4ap Drug
1 trials

US sites by state

Facility locations filed on MCI trials. A trial with sites in several states counts in each.

California 3 trials
Pennsylvania 1 trials
North Carolina 1 trials
Connecticut 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MCI page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MCI condition card totals 6 registered trials; most-linked intervention MediTrain; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.